TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39372369

Group type: EXPERIMENTAL
Intervention: KETO diet (carbohydrate restriction-induced LDL-C ≥190 mg/dL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: MiHeart controls (lower LDL-C)
Number of subjects: 80
Study: 39373062

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 139
Study: 39373144

Group type: EXPERIMENTAL
Intervention: Yoga-based intervention targeting anger management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39373164

Group type: EXPERIMENTAL
Intervention: Sustained Virological Response (SVR) group (n=54)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Very Low-Level Viraemia (VLLV) group (n=30)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Occasionally Low-Level Viraemia (OLLV) group (n=17)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Multiple Low-Level Viraemia (MLLV) group (n=10)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Non-VLLV (including MLLV)
Number of subjects: 111

Group type: COMPARATOR
Intervention: LLV group
Number of subjects: 111
Study: 39373173

Group type: EXPERIMENTAL
Intervention: FIT threshold of 15 μg/g
Number of subjects: 47265

Group type: EXPERIMENTAL
Intervention: FIT threshold of 47 μg/g
Number of subjects: 47265

Group type: EXPERIMENTAL
Intervention: FIT threshold of 150 μg/g
Number of subjects: 47265

Group type: EXPERIMENTAL
Intervention: Detection rate of stage I CRC
Number of subjects: 47265

Group type: EXPERIMENTAL
Intervention: Post-colonoscopy bleeding rates
Number of subjects: 47265
Study: 39373311

Group type: EXPERIMENTAL
Intervention: BI 1820237 (0.075-2.4 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: BI 1820237 (1.2 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BI 1820237 (0.025-1.2 mg) + liraglutide (0.6 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 39373498

Group type: EXPERIMENTAL
Intervention: Post-natal antibiotic exposure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Antibiotic-naive infants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall presence of antibiotic resistance genes (ARGs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preterm infants without direct or intrapartum antibiotic exposure
Number of subjects: 30
Study: 39373766

Group type: EXPERIMENTAL
Intervention: Interactive online group programme combining pain neuroscience education (PNE) and graded exposure to movement (GEM) for 12 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study: 39373831

Group type: EXPERIMENTAL
Intervention: Hello Bundle intervention (6 components: Hello campaign posters, email reminders, integrating greetings in morning huddles, hello jars, lead-by-example initiatives, daily updated hello board)
Number of subjects: 7300

Group type: EXPERIMENTAL
Intervention: Hello Bundle intervention
Number of subjects: 7300
Study: 39373843

Group type: EXPERIMENTAL
Intervention: STS101 (5.2 mg dihydroergotamine nasal powder)
Number of subjects: 344
Study: 39373844

Group type: EXPERIMENTAL
Intervention: Viloxazine ER (extended-release capsules) at doses between 200 and 600 mg/day
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Viloxazine ER (extended-release capsules) at doses ≥ 400 mg/day
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Viloxazine ER (extended-release capsules)
Number of subjects: 159
Study: 39373998

Group type: EXPERIMENTAL
Intervention: Lap position (hand supported on lap)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Side position (arm unsupported at the side)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Desk position (desk 1; reference)
Number of subjects: 133
Study: 39374004

Group type: EXPERIMENTAL
Intervention: Masked taper plus cognitive behavioral therapy-augmented program (MTcap)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard CBTI plus supervised (unmasked) gradual taper (SGT)
Number of subjects: 188
Study: 39374016

Group type: EXPERIMENTAL
Intervention: COMPASS (Community Participation Transition after Stroke) program
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (attentional control)
Number of subjects: 185
Study: 39374130

Group type: EXPERIMENTAL
Intervention: Individualized Assessment and Treatment Program (IATP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CaseM
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCBT
Number of subjects: 0
Study: 39374216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE) supervised by a physiotherapist twice a week for 12 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Neck-specific exercise with internet support and four physiotherapy visits (NSEIT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: NSEIT and NSE
Number of subjects: 140
Study: 39374319

Group type: EXPERIMENTAL
Intervention: Thrombectomy (n=152)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual medical care (Control, n=148)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Thrombectomy (n=151)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual medical care (Control, n=149)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Thrombectomy (n=148)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual medical care (Control, n=146)
Number of subjects: 300
Study: 39374480

Group type: EXPERIMENTAL
Intervention: Matched targeted therapies (MTTs) post-MTB evaluation
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Approved tyrosine kinase inhibitors
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy/immunotherapy
Number of subjects: 283

Group type: COMPARATOR
Intervention: No matched targeted therapy (MTT)
Number of subjects: 283
Study: 39374521

Group type: EXPERIMENTAL
Intervention: Asciminib 80 mg daily plus dasatinib 140 mg daily plus prednisone 60 mg/m2 daily
Number of subjects: 24
Study: 39374532

Group type: EXPERIMENTAL
Intervention: Pitavastatin, 4 mg daily
Number of subjects: 7731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7731
Study: 39374535

Group type: EXPERIMENTAL
Intervention: R-chemo (rituximab-chemotherapy)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: R2 (rituximab-lenalidomide)
Number of subjects: 324

Group type: COMPARATOR
Intervention: FL20 (20-gene predictor)
Number of subjects: 324

Group type: COMPARATOR
Intervention: FLcm assay (using FOXP1, LMO2, CD22, and MUM1 antibodies)
Number of subjects: 324
Study: 39374548

Group type: EXPERIMENTAL
Intervention: Enhanced recovery thoracoscopic wedge resection (ERAS 3-port VATS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increase in FEV1%pre by 1%
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increase in DLCO%pre by 1%
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Each additional pack-year
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 150
Study: 39374555

Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Intervention (Brief MI) - 15-minute audio mindfulness practice daily from embryo transfer to pregnancy test (total 180-210 minutes)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Extremely Brief Meditation (EBMI) - Weekly 40-minute sessions with a meditator instructor (total 80 minutes)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control Group (CG) - No specific intervention mentioned
Number of subjects: 68
Study: 39374573

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical hematopoietic stem cell transplantation
Number of subjects: 18
Study: 39374601

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 984

Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 984
Study: 39374605

Group type: EXPERIMENTAL
Intervention: Booster group (received homologous booster dose at month 18)
Number of subjects: 248

Group type: COMPARATOR
Intervention: No-booster group (received no booster)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Booster group
Number of subjects: 248

Group type: COMPARATOR
Intervention: No-booster group
Number of subjects: 248
Study: 39374638

Group type: EXPERIMENTAL
Intervention: Early 3-month direct oral anticoagulant (DOAC) therapy followed by single antiplatelet therapy (experimental arm)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Lifelong single antiplatelet therapy (standard arm)
Number of subjects: 324
Study: 39374788

Group type: EXPERIMENTAL
Intervention: Composite intravenous lipid emulsion (CO-ILE) with fish oil
Number of subjects: 161

Group type: COMPARATOR
Intervention: Pure soybean oil lipid emulsion (SOLE)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CO-ILE
Number of subjects: 161

Group type: COMPARATOR
Intervention: SOLE
Number of subjects: 161
Study: 39374820

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 8 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 8 weeks in ME/CFS group
Number of subjects: 33
Study: 39375057

Group type: EXPERIMENTAL
Intervention: Mobile application-based digital therapeutics for supportive care after gastrectomy
Number of subjects: 39
Study: 39375058

Group type: EXPERIMENTAL
Intervention: Soybean/tofu consumption
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Soybean paste stew consumption
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Frequent consumption of soybean paste stew (≥5 times/week)
Number of subjects: 5535
Study: 39375168

Group type: EXPERIMENTAL
Intervention: Combination treatment with avutometinib plus defactinib
Number of subjects: 270

Group type: COMPARATOR
Intervention: Investigator's choice of treatment
Number of subjects: 270
Study: 39375173

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 10244
Study: 39375179

Group type: EXPERIMENTAL
Intervention: Folic acid (400 mcg) and vitamin B supplementation for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39375184

Group type: EXPERIMENTAL
Intervention: Patient-reported symptom scores combined with a faecal calprotectin (FC) home test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopy (gold standard)
Number of subjects: 0
Study: 39375281

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 1249
Study: 39375290

Group type: EXPERIMENTAL
Intervention: CAB+RPV LA
Number of subjects: 670

Group type: COMPARATOR
Intervention: BIC/FTC/TAF
Number of subjects: 670
Study: 39375322

Group type: EXPERIMENTAL
Intervention: Environmental awareness-based education
Number of subjects: 110
Study: 39375488

Group type: EXPERIMENTAL
Intervention: Seropositive group (n:30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Seronegative group (n:30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n:30)
Number of subjects: 90
Study: 39375517

Group type: EXPERIMENTAL
Intervention: Print materials + loaner iPad device with data plan coverage (n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Print materials + loaner device + up to six, 15-20-minute motivational interviewing-based coaching calls (n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Print materials (control, n=30)
Number of subjects: 90
Study: 39375627

Group type: EXPERIMENTAL
Intervention: Nature-based social intervention once a week for nine weeks (n=162)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual care (n=157)
Number of subjects: 319
Study: 39375634

Group type: EXPERIMENTAL
Intervention: Vestibular socket therapy (VST) in infected sockets (group I)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vestibular socket therapy (VST) in non-infected sockets (group N)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of infected (group I) and non-infected (group N) sockets
Number of subjects: 26
Study: 39375710

Group type: EXPERIMENTAL
Intervention: Smoke-Free Home SafeCare (SFHSC); n=25
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard SafeCare (active treatment control); n=25
Number of subjects: 500
Study: 39375728

Group type: EXPERIMENTAL
Intervention: ActiveCBT (8-week CBT intervention primed with 30 min of moderate-intensity aerobic exercise)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CalmCBT (8-week CBT intervention while resting for 30 min before CBT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ActiveCBT and CalmCBT
Number of subjects: 40
Study: 39375781

Group type: EXPERIMENTAL
Intervention: Supramaximal high-intensity interval training (HIIT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Supramaximal HIIT and MICT
Number of subjects: 162
Study: 39375869

Group type: EXPERIMENTAL
Intervention: Dapagliflozin/linagliptin fixed-dose combination (FDC [AJU-A51]) 10/5 mg/day (n=117)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Linagliptin 5 mg plus placebo (n=118)
Number of subjects: 235
Study: 39375952

Group type: EXPERIMENTAL
Intervention: ABL001/CTX-009 (10 mg/kg every other week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABL001/CTX-009 (15 mg/kg every three weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weight-based dosing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fixed dosing
Number of subjects: 30
Study: 39376152

Group type: EXPERIMENTAL
Intervention: LEAP! Rx (exercise and monthly brain health education)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard-of-care control group
Number of subjects: 219
Study: 39376156

Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus obinutuzumab (ZO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obinutuzumab (O)
Number of subjects: 0
Study: 39376771

Group type: EXPERIMENTAL
Intervention: Lidocaine 2.0% infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline 0.9% infusion
Number of subjects: 40
Study: 39376791

Group type: EXPERIMENTAL
Intervention: Hypotonic fluids (NaCl <130 mmol/L)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Isotonic fluids (NaCl = 130-154 mmol/L)
Number of subjects: 420
Study: 39376864

Group type: EXPERIMENTAL
Intervention: Ethos OART platform delivering multi-site pulsed hypofractionated radiotherapy (40 Gy in 5 fractions) in combination with standard of care (SOC) chemoimmunotherapy.
Number of subjects: 1
Study: 39377069

Group type: EXPERIMENTAL
Intervention: EUS-CDS
Number of subjects: 20

Group type: COMPARATOR
Intervention: EUS-HGS
Number of subjects: 20
Study: 39377148

Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor administered via nasogastric tube
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ticagrelor in resuscitated patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AR-C124910XX in resuscitated patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ticagrelor in semi-urgent CABG patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AR-C124910XX in semi-urgent CABG patients
Number of subjects: 20
Study: 39377226

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of IgG1 NANP binding magnitude plus serum NANP and N-junction Ig binding magnitude-avidity composite
Number of subjects: 0
Study: 39377442

Group type: EXPERIMENTAL
Intervention: Fetuses with fetal growth restriction (FGR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normally developed fetuses
Number of subjects: 0
Study: 39377681

Group type: EXPERIMENTAL
Intervention: Black Bone (BB) MRI sequence
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Zero Echo Time (ZTE) MRI sequence
Number of subjects: 47

Group type: COMPARATOR
Intervention: Whole-body CT (reference standard)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ZTE MRI sequence
Number of subjects: 47
Study: 39377880

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 treatments (~ 2 years)
Number of subjects: 55
Study: 39377970

Group type: EXPERIMENTAL
Intervention: trametinib in a redifferentiation trial
Number of subjects: 5

Group type: COMPARATOR
Intervention: no redifferentiation therapy
Number of subjects: 5
Study: 39378042

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg once daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 204
Study: 39378065

Group type: EXPERIMENTAL
Intervention: Calaspargase pegol-mnkl and cobimetinib
Number of subjects: 0
Study: 39378066

Group type: EXPERIMENTAL
Intervention: Family-centered group program (FAME)
Number of subjects: 10
Study: 39378079

Group type: EXPERIMENTAL
Intervention: Ophthalmic acupuncture with 'De Qi' sensation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Minimum acupuncture stimulation on nonophthalmic acupoints
Number of subjects: 50
Study: 39378080

Group type: EXPERIMENTAL
Intervention: Adaptive messaging group receiving text messages selected by a reinforcement learning algorithm daily
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Adaptive messaging group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Random messaging group receiving randomly selected feedback and motivational text messages daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group receiving a weekly mood monitoring message
Number of subjects: 168
Study: 39378100

Group type: EXPERIMENTAL
Intervention: Parent Positive app
Number of subjects: 646

Group type: COMPARATOR
Intervention: Follow-up as usual
Number of subjects: 646
Study: 39378124

Group type: EXPERIMENTAL
Intervention: Dual hypothermic oxygenated machine perfusion (DHOPE)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: DHOPE
Number of subjects: 119
Study: 39378125

Group type: EXPERIMENTAL
Intervention: CAM2029 (n=48)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (n=24)
Number of subjects: 72
Study: 39378234

Group type: EXPERIMENTAL
Intervention: Perturbing group (n = 18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 54
Study: 39378237

Group type: EXPERIMENTAL
Intervention: Breathing and relaxation technique in antenatal education class
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antenatal education class
Number of subjects: 0
Study: 39378281

Group type: EXPERIMENTAL
Intervention: 4-week loading dose of 300 mg clofazimine once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6-week loading dose regimen
Number of subjects: 12
Study: 39378326

Group type: EXPERIMENTAL
Intervention: IM20×3 group (3 standard doses of 20 μg at 0-1-6 months)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: IM20×4 group (4 standard doses of 20 μg at 0-1-2-6 months)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: IM60×4 group (4 triple doses of 60 μg at 0-1-2-6 months)
Number of subjects: 504
Study: 39378385

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39378386

Group type: EXPERIMENTAL
Intervention: Osimertinib plus Ramucirumab (arm A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Osimertinib alone (arm B)
Number of subjects: 160
Study: 39378393

Group type: EXPERIMENTAL
Intervention: 30 Gy
Number of subjects: 281

Group type: COMPARATOR
Intervention: 27.5 Gy
Number of subjects: 281
Study: 39378423

Group type: EXPERIMENTAL
Intervention: Minimally invasive manual, robot-assisted, or traditional open surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative technologies and treatment pathways
Number of subjects: 0
Study: 39378432

Group type: EXPERIMENTAL
Intervention: RehaPlus+ (personalized eHealth program)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Usual care (conventional physician-assisted outpatient program)
Number of subjects: 169
Study: 39378565

Group type: EXPERIMENTAL
Intervention: Dostarlimab (DCT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Pembrolizumab (PCT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Dostarlimab (DCT) and Pembrolizumab (PCT)
Number of subjects: 201
Study: 39379314

Group type: EXPERIMENTAL
Intervention: Stent retriever as first line endovascular thrombectomy (EVT) approach
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Aspiration as first line endovascular thrombectomy (EVT) approach
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: IV tenecteplase with aspiration
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: IV tenecteplase with stent retriever
Number of subjects: 435

Group type: COMPARATOR
Intervention: IV alteplase with aspiration
Number of subjects: 435

Group type: COMPARATOR
Intervention: IV alteplase with stent retriever
Number of subjects: 435
Study: 39379327

Group type: EXPERIMENTAL
Intervention: Non-compliance with the ERAS protocol
Number of subjects: 600

Group type: COMPARATOR
Intervention: Compliance with the ERAS protocol
Number of subjects: 600
Study: 39379403

Group type: EXPERIMENTAL
Intervention: Viltolarsen 80 mg/kg intravenous once weekly for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cohort (external control group-matched for multiple variables)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viltolarsen
Number of subjects: 0
Study: 39379413

Group type: EXPERIMENTAL
Intervention: Neural mobilization of the sciatic nerve and its branches (posterior tibial nerve, lateral dorsocutaneous, medial and intermediate dorsocutaneous nerves)
Number of subjects: 18
Study: 39379462

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 9
Study: 39379540

Group type: EXPERIMENTAL
Intervention: Peroral antibiotics (3-day course)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 54
Study: 39379569

Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 42

Group type: COMPARATOR
Intervention: BM aspiration and biopsy (BMAB)
Number of subjects: 42
Study: 39379672

Group type: EXPERIMENTAL
Intervention: Modified furosemide responsiveness index (mFRI)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Combination of mFRI and urinary injury biomarkers (uNAG or uNGAL)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Incorporating mFRI and renal biomarkers into clinical model
Number of subjects: 1013
Study: 39379705

Group type: EXPERIMENTAL
Intervention: Prasinezumab (delayed start)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Prasinezumab (early start)
Number of subjects: 271
Study: 39379797

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (lactobacillus) with lifestyle modification for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard Treatment (low-fat diet and lifestyle modification)
Number of subjects: 50